Trial document




drksid header

  DRKS00009443

Trial Description

start of 1:1-Block title

Title

Barostim Therapy™ in Heart Failure with Preserved Ejection Fraction (HFrEF): A Data Collection Registry with the CE-Marked Barostim neo™ System

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

HFrEF Registry

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This registry is a collection of data in patients with an already implanted Barostim Therapy neo device for the treatment of hypertension and concomitant heart failure. The device itself is already approved for the treatment. At the following times data about the treatment are collected: before the device was implanted, and after 3, 6 and 12 months after the device was turned on.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The purpose of this registry is to measure the effect of Barostim Therapy with the Barostim Neo system in the commercial setting in subjects implanted under the CE Marked indication for heart failure with reduced ejection fraction (HFrEF).

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00009443
  •   2015/10/05
  •   [---]*
  •   no
  •   Approved
  •   Nr. 6956, Ethikkommission der Medizinischen Hochschule Hannover
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   360049  ((CVRx Incorporated))
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   I50.9 -  Heart failure, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Post-Market-Registerstudie: Patients with an implanted Barostim neo-system in accordance with CE-approved criteria for heart failure with reduced ejection fraction. Data regarding heart failure and device function will be collected at 3, 6 and 12 months after activation and will be compared to data prior to the implantation.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

The primary efficacy evaluation will be the following values at six month relative to baseline:

a) change in the extent of heart failure (NYHA class)
b) Quality of Life as measured by the Minnesota Living with Heart Failure Questionnaire
c) assessing the performance of a patient below the anaerobic threshold by using the Six-Minute Hall Walk

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Secondary Objectives
1. The following data at 12 months compared to pre-implant baseline:
a. Extend of heartfailure measured by NYHA Class
b. Quality of Life with the Minnesota Living with Heart failure Questionnaire
c. Performance of the patient assed with the Six-Minute Hall Walk
d. Biomarker for grade of heart falure (NT-pro-BNP)
e. Heartfunction assessed with Left ventricular ejection fraction (LVEF)
2. The rate of all-cause mortality and cardiovascular mortality at 12 months
3. The following data at 12 months compared to to the 12 months period pre-implant:
a. Heart failure hospitalization
b. Number of episodes
c. Total days hospitalized
d. Total cost of hospitalization
e. Incidence of ventricular and atrial tachyarrhythmias

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Italy
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2017/04/07
  •   500
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

To be eligible for this registry, subjects must meet all of the following inclusion criteria:
1. Implanted with the Barostim Neo system per the CE-Mark approved criteria for heart failure at any time in the past.
2. On stable, maximally-tolerated, guideline-directed heart failure medications for at least 30 days prior to implant, where stable is defined as:
• No more than a 100% increase or a 50% decrease of the dosage of any one medication other than a diuretic.
• Medication changes within a drug class are allowed as long as the equivalent dosage is within the limits specified above.
• Unrestricted changes in diuretics are allowed as long as the subject remains on a diuretic.
3. Signed a CVRx-approved informed consent form for the registry.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Patient does not meet inclusion criteria

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • CVRx Incorporated
    • 9201 West Broadway Avenue, Suite 650
    • MN 55445  Minneapolis
    • United States
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • CVRx Incorporated
    • Ms.  Liz  Galle 
    • 9201 West Broadway Avenue, Suite 650
    • MN 55445  Minneapolis
    • United States
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • CVRx Incorporated
    • Ms.  Liz  Galle 
    • 9201 West Broadway Avenue, Suite 650
    • MN 55445  Minneapolis
    • United States
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • CVRx Incorporated
    • 9201 West Broadway Avenue, Suite 650
    • MN 55445  Minneapolis
    • United States
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.